A citation-based method for searching scientific literature

James J Harding, Maeve A Lowery, Alan H Shih, Juan M Schvartzman, Shengqi Hou, Christopher Famulare, Minal Patel, Mikhail Roshal, Richard K Do, Ahmet Zehir, Daoqi You, S Duygu Selcuklu, Agnes Viale, Martin S Tallman, David M Hyman, Ed Reznik, Lydia W S Finley, Elli Papaemmanuil, Alessandra Tosolini, Mark G Frattini, Kyle J MacBeth, Guowen Liu, Bin Fan, Sung Choe, Bin Wu, Yelena Y Janjigian, Ingo K Mellinghoff, Luis A Diaz, Ross L Levine, Ghassan K Abou-Alfa, Eytan M Stein, Andrew M Intlekofer. Cancer Discov 2018
Times Cited: 84

List of co-cited articles
1183 articles co-cited >1

Times Cited
  Times     Co-cited

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Andrew M Intlekofer, Alan H Shih, Bo Wang, Abbas Nazir, Ariën S Rustenburg, Steven K Albanese, Minal Patel, Christopher Famulare, Fabian M Correa, Naofumi Takemoto,[...]. Nature 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010

Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Nicola D Roberts, Nicola E Potter, Michael Heuser, Felicitas Thol, Niccolo Bolli,[...]. N Engl J Med 2016

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Lynn Quek, Muriel D David, Alison Kennedy, Marlen Metzner, Michael Amatangelo, Alan Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens,[...]. Nat Med 2018

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Michael D Amatangelo, Lynn Quek, Alan Shih, Eytan M Stein, Mikhail Roshal, Muriel D David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A Bernard,[...]. Blood 2017

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Katharine Yen, Jeremy Travins, Fang Wang, Muriel D David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin,[...]. Cancer Discov 2017

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Gail J Roboz, Manish R Patel, Robert Collins, Ian W Flinn,[...]. Blood 2019

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Sung Choe, Hongfang Wang, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Justin M Watts, Daniel A Pollyea,[...]. Blood Adv 2020

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Steven M Chan, Daniel Thomas, M Ryan Corces-Zimmerman, Seethu Xavy, Suchita Rastogi, Wan-Jen Hong, Feifei Zhao, Bruno C Medeiros, David A Tyvoll, Ravindra Majeti. Nat Med 2015

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Alice S Mims, Gabrielle T Prince, Jessica K Altman, Martha L Arellano, Will Donnellan, Harry P Erba,[...]. Blood 2020

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser,[...]. Science 2013

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson,[...]. Blood 2017

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Amir T Fathi, Courtney D DiNardo, Irina Kline, Laurie Kenvin, Ira Gupta, Eyal C Attar, Eytan M Stein, Stephane de Botton. JAMA Oncol 2018

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D DiNardo, Keith Pratz, Vinod Pullarkat, Brian A Jonas, Martha Arellano, Pamela S Becker, Olga Frankfurt, Marina Konopleva, Andrew H Wei, Hagop M Kantarjian,[...]. Blood 2019

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui,[...]. ACS Med Chem Lett 2018

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L Ricker,[...]. Cancer Discov 2016

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Courtney D DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan Kadia, Mark Routbort, Keyur P Patel, Mark Brandt, Sherry Pierce,[...]. Am J Hematol 2015

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Julie-Aurore Losman, Ryan E Looper, Peppi Koivunen, Sungwoo Lee, Rebekka K Schneider, Christine McMahon, Glenn S Cowley, David E Root, Benjamin L Ebert, William G Kaelin. Science 2013

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B Holland, Susan P Whitman, Heiko Becker, Sebastian Schwind,[...]. J Clin Oncol 2010

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, S Kaulfuss, O Panknin, K Zimmermann, L Toschi,[...]. Leukemia 2017

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, Hector U Lopez, Valeria R Fantin, Kimberly S Straley, David P Schenkein, Aram F Hezel, Marek Ancukiewicz, Hannah M Liebman,[...]. Oncologist 2012

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Rasheduzzaman Chowdhury, Kar Kheng Yeoh, Ya-Min Tian, Lars Hillringhaus, Eleanor A Bagg, Nathan R Rose, Ivanhoe K H Leung, Xuan S Li, Esther C Y Woon, Ming Yang,[...]. EMBO Rep 2011

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert Collins, Anthony S Stein, Mark G Frattini, Qiang Xu, Alessandra Tosolini, Wendy L See,[...]. Leukemia 2019

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Maeve A Lowery, Howard A Burris, Filip Janku, Rachna T Shroff, James M Cleary, Nilofer S Azad, Lipika Goyal, Elizabeth A Maher, Lia Gore, Antoine Hollebecque,[...]. Lancet Gastroenterol Hepatol 2019

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, Kristina Laumann, Susan Geyer, Clara D Bloomfield, Christian Thiede, Thomas W Prior, Konstanze Döhner, Guido Marcucci,[...]. N Engl J Med 2017

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Peter Paschka, Richard F Schlenk, Verena I Gaidzik, Marianne Habdank, Jan Krönke, Lars Bullinger, Daniela Späth, Sabine Kayser, Manuela Zucknick, Katharina Götze,[...]. J Clin Oncol 2010

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.
Young Shin Cho, Julian R Levell, Gang Liu, Thomas Caferro, James Sutton, Cynthia M Shafer, Abran Costales, James R Manning, Qian Zhao, Martin Sendzik,[...]. ACS Med Chem Lett 2017

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, Amir T Fathi, Olga Frankfurt, Andre C Schuh, Hartmut Döhner, Giovanni Martinelli, Prapti A Patel, Emmanuel Raffoux,[...]. J Clin Oncol 2021

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
P Wang, Q Dong, C Zhang, P-F Kuan, Y Liu, W R Jeck, J B Andersen, W Jiang, G L Savich, T-X Tan,[...]. Oncogene 2013

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
M Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, Stephen Damato, Dina Halai, Fitim Berisha, Robin Pollock, Paul O'Donnell, Anita Grigoriadis, Tim Diss,[...]. J Pathol 2011

Acute Myeloid Leukemia.
Hartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield. N Engl J Med 2015

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Jay P Patel, Mithat Gönen, Maria E Figueroa, Hugo Fernandez, Zhuoxin Sun, Janis Racevskis, Pieter Van Vlierberghe, Igor Dolgalev, Sabrena Thomas, Olga Aminova,[...]. N Engl J Med 2012

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshad Farshidfar, Siyuan Zheng, Marie-Claude Gingras, Yulia Newton, Juliann Shih, A Gordon Robertson, Toshinori Hinoue, Katherine A Hoadley, Ewan A Gibb, Jason Roszik,[...]. Cell Rep 2017

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Chaitanya R Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C Kang, Jacqueline Weatherly, Mingxin Zuo, Ralph Zinner, David Hong, Funda Meric-Bernstam,[...]. PLoS One 2014

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.